


Linda De Jesus, SVP and Chief Commercial Officer





Building on a strong foundation

Integrated go-to-market model

Accelerating growth strategy

Serving an Impressive Roster of Global Customers





served by Azenta



trust Azenta with

their samples



Best-selling pharma products: clinical samples managed by SRS


Top 5



US molecular biologists use Azenta*



Citations in scientific journals



Pharma / Biotech











Leading Customers Include:

Healthcare / Clinical







Academic / Government














Well-Positioned in Key Global Life Science Markets





High Impact Innovations from Azenta



Antibody Therapeutics



- Single-cell antibody discovery platform
- Synthetic DNA libraries for lead optimization

Cell & Gene Therapy



- Automated cryogenic storage
- Proprietary AAV sequencing protocols (AAV-ITR & NGS whole genome seq)

High-throughput Screening



- Automation-friendly consumables & instruments
- Proprietary highthroughput NGS screens, RNA-seq & WGS

Vaccine Development



- Expedited DNA synthesis & libraries
- Clinical trials sample collection & management

Discover, develop and deliver faster



Building on a strong foundation

Integrated go-to-market model

Accelerating growth strategy

Our New Go-to-Market Model, One Unified Approach



New Life Science Brand



- Strong value proposition
- Strategic focus
- Advanced therapeutics

Commercial Acceleration



- Consolidated customer-centric approach
- Enterprise strategic accounts
- Geographic expansion
 China, APAC, EMEA

Unique Value Proposition



- Integrated Life Sciences Sample Exploration and Management Solutions
- Informatics and digital capabilities
- Integrated workflow solutions serving novel modularities

Commercial Organization Transformation



Prior

Go-to-Market

- Many brand names
- Strong but disjointed

Sales

- Technology specific
- Regional key accounts

Marketing

- Downstream execution
- De-centralized by business

Commercial Excellence

- Transactional
- Disjointed processes

New Azenta Model

- Clear value proposition under one brand name
- Integrated portfolio
- Cross-trained to sell entire portfolio
- Enterprise selling approach
- Integrated and centralized
- Modernized with digital automation
- Customer centric streamlined process
- Management by KPI discipline



Building on a strong foundation

Integrated Go-to-market model

Accelerating growth strategy

Our Growth Strategies









Customer-centric commercial model

Solution-based approach

Geographic expansion







Deepening Client Relationships with New Customer-Centric (Commercial Model





Corporate Accounts

- Strategic global accounts
- Enterprise level partnership





- Regionally integrated go-to-market coverage
- Streamlined sales support and specialist teams



Multi-Channels Strategy

- Transactional sales with inside sales and e-channel
- Extend market reach through channel expansion and digital



Rest-of-Market

Commercial

Broadest Capability Set – Solutions at Every Phase of Development



Cell and Gene Therapy (C>) Example:

Research & Development Discover targets and identify therapeutic leads • AAV plasmid synthesis and ITR sequencing • Transcriptome analysis with RNA-Seq • Gene synthesis and viral production

Pre-clinical & Clinical

Test candidates in animal and clinical research studies

- Retention sample storage and testing
- Viral whole genome sequencing
- GLP-level CRISPR sequencing



Manufacturing & Distribution

Logistics, transport and storage of manufactured product

- Automated cryogenic storage systems and reporting
- Drug product and cell therapy storage and logistics



Therapies




Azenta provides advanced, agile technology to enable validation, optimization and production scale-up

Significant Investment to Expand Market Reach



13



A New Integrated Playbook. Accelerating Growth



